Journal of Cutaneous Pathology 2014-Jul
Ponatinib-induced neutrophilic panniculitis.
Csak regisztrált felhasználók fordíthatnak cikkeket
Belépés Regisztrálás
A hivatkozás a vágólapra kerül
Kulcsszavak
Absztrakt
Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.